Formulation factors affecting the release of ezetimibe from different liquisolid compacts

Liquisolid technique is one of the methods used to improve the dissolution rate of the poorly water soluble drugs utilizing non volatile liquids. Enhancement of the release of ezetimibe from different liquisolid formulations. Four liquid vehicles were used to prepare the liquid medications with diff...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical development and technology Vol. 18; no. 2; p. 417
Main Authors Khanfar, M, Sheikh Salem, M, Hawari, R
Format Journal Article
LanguageEnglish
Published England 01.03.2013
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Liquisolid technique is one of the methods used to improve the dissolution rate of the poorly water soluble drugs utilizing non volatile liquids. Enhancement of the release of ezetimibe from different liquisolid formulations. Four liquid vehicles were used to prepare the liquid medications with different drug concentrations. The interaction between the drug and the excipients in liquisolid powders were characterized by DSC, X-ray, FTIR and SEM. Furthermore, the powder characteristics were evaluated by Carr's Index and powder wetting time determinations, respectively. All prepared formulations were compressed at different pressures to end with the same constant porosity and the tablets were evaluated by different tests and compared with conventional formula. No interaction had been detected in all liquisolid formulations as shown in the results of XRD, FTIR, DSC and SEM. In addition to that, all liquisolid compacts had expressed faster dissolution profiles compared with that of conventional formula. The dissolution rate was affected by the drug concentration, solubility of the drug in the liquid vehicle and type of carrier. In addition, the presence of the liquid vehicle has been found to affect the mechanical properties of the liquisolid formulations.
AbstractList Liquisolid technique is one of the methods used to improve the dissolution rate of the poorly water soluble drugs utilizing non volatile liquids. Enhancement of the release of ezetimibe from different liquisolid formulations. Four liquid vehicles were used to prepare the liquid medications with different drug concentrations. The interaction between the drug and the excipients in liquisolid powders were characterized by DSC, X-ray, FTIR and SEM. Furthermore, the powder characteristics were evaluated by Carr's Index and powder wetting time determinations, respectively. All prepared formulations were compressed at different pressures to end with the same constant porosity and the tablets were evaluated by different tests and compared with conventional formula. No interaction had been detected in all liquisolid formulations as shown in the results of XRD, FTIR, DSC and SEM. In addition to that, all liquisolid compacts had expressed faster dissolution profiles compared with that of conventional formula. The dissolution rate was affected by the drug concentration, solubility of the drug in the liquid vehicle and type of carrier. In addition, the presence of the liquid vehicle has been found to affect the mechanical properties of the liquisolid formulations.
Author Sheikh Salem, M
Khanfar, M
Hawari, R
Author_xml – sequence: 1
  givenname: M
  surname: Khanfar
  fullname: Khanfar, M
  email: mskhanfar@just.edu.jo
  organization: Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan. mskhanfar@just.edu.jo
– sequence: 2
  givenname: M
  surname: Sheikh Salem
  fullname: Sheikh Salem, M
– sequence: 3
  givenname: R
  surname: Hawari
  fullname: Hawari, R
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22530561$$D View this record in MEDLINE/PubMed
BookMark eNo1j09LxDAUxIMo7h_9BiL5Al3fS5MmPcriqrDgRQ-eljR90UjbrEl70E9vQT3NwAw_ZlbsdIgDMXaFsCkR6hsEU2qpYCMAxaYyoGp5wpZzpIvaVHrBVjl_AKCpQZ2zhRCqBFXhkr3uYuqnzo4hDtxbN8aUufWe3BiGNz6-E0_Ukc3Eo-f0TWPoQ0Pcp9jzNszFRMPIu_A5hRy70HIX--PMyRfszNsu0-WfrtnL7u55-1Dsn-4ft7f7wkk0YyE1giPpbDU7R61oynl_KVqFKE0DJDx6iVrP47WXrZNSEWhlKkQFxoo1u_7lHqemp_ZwTKG36evw_1H8AGvjVIM
CitedBy_id crossref_primary_10_1080_10717544_2016_1250140
crossref_primary_10_1007_s40005_016_0236_1
crossref_primary_10_53879_id_58_01_12717
crossref_primary_10_1016_j_xphs_2022_08_033
crossref_primary_10_53879_id_59_01_12769
crossref_primary_10_1208_s12249_020_01754_5
crossref_primary_10_1016_j_powtec_2018_01_068
crossref_primary_10_1517_17425247_2014_877885
crossref_primary_10_4155_tde_2019_0063
crossref_primary_10_1016_j_ijpharm_2021_121277
crossref_primary_10_4155_tde_2019_0020
crossref_primary_10_3390_pharmaceutics14091787
crossref_primary_10_15171_bi_2017_02
crossref_primary_10_52711_2231_5659_2022_00018
crossref_primary_10_1007_s13346_018_0514_8
crossref_primary_10_52711_2231_5659_2024_00010
crossref_primary_10_1080_01932691_2020_1842211
crossref_primary_10_1007_s40005_015_0225_9
crossref_primary_10_3390_pharmaceutics11120647
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.3109/10837450.2012.680594
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1097-9867
ExternalDocumentID 22530561
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
00X
03L
0BK
0R~
123
29O
36B
4.4
53G
5VS
8V8
AACCU
AALIY
AALUX
AAPUL
AAPXX
AAQRR
ABBKH
ABCRQ
ABEIZ
ABJNI
ABLIJ
ABLKL
ABUPF
ABXYU
ACENM
ACGEJ
ACGFS
ACLSK
ADCVX
ADRBQ
ADXPE
AECIN
AEMOZ
AENEX
AEOZL
AFAUU
AFKVX
AFQCT
AFWLO
AGAFX
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AIRBT
AJEBJ
AJWEG
AJXHO
AKBVH
AKVCP
ALMA_UNASSIGNED_HOLDINGS
ALQZU
ALYBC
AWYRJ
BABNJ
BLEHA
BOHLJ
BVLLS
CAG
CCCUG
CGR
COF
CS3
CUY
CVF
DEIEU
DKSSO
DLVIE
DTRLO
DU5
DZHFC
EBD
EBO
EBR
EBS
EBU
ECM
EHE
EIF
EJD
EMB
EMK
EMOBN
EPL
F5P
HZ~
JFOCU
K1G
KRBQP
KWAYT
KYCEM
LJTGL
M44
M4Z
MK0
NPM
NUSFT
O9-
P2P
QRXOQ
RNANH
RVRKI
SV3
TBQAZ
TERGH
TFDNU
TFL
TFW
TH9
UHWXJ
V1S
~1N
ID FETCH-LOGICAL-c418t-4710ce4ca6471ced2b368032d51148b0e2f1f41770187f4dc445e0758611508a2
IngestDate Thu May 23 23:18:11 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c418t-4710ce4ca6471ced2b368032d51148b0e2f1f41770187f4dc445e0758611508a2
PMID 22530561
ParticipantIDs pubmed_primary_22530561
PublicationCentury 2000
PublicationDate 2013-03-01
PublicationDateYYYYMMDD 2013-03-01
PublicationDate_xml – month: 03
  year: 2013
  text: 2013-03-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Pharmaceutical development and technology
PublicationTitleAlternate Pharm Dev Technol
PublicationYear 2013
SSID ssj0018905
Score 2.1140091
Snippet Liquisolid technique is one of the methods used to improve the dissolution rate of the poorly water soluble drugs utilizing non volatile liquids. Enhancement...
SourceID pubmed
SourceType Index Database
StartPage 417
SubjectTerms Azetidines - chemistry
Chemistry, Pharmaceutical - methods
Drug Compounding - methods
Excipients - chemistry
Ezetimibe
Liquid Crystals - chemistry
Porosity
Powders - chemistry
Solubility
Tablets - chemistry
Title Formulation factors affecting the release of ezetimibe from different liquisolid compacts
URI https://www.ncbi.nlm.nih.gov/pubmed/22530561
Volume 18
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwELZ4XLggHsvylg-IC6SbOE7iHBECIRAI7RaJPaHYHqsRtIAIQu2vZxznUQqIXS5RFEeRm-_rdGY63wwhO0KnodQ89EIWgceNZB7CLL0sUakIItAJtwLn84v45IqfXkfXbVapVJcUsqNGH-pKvoMqXkNcrUr2P5BtHooX8BzxxSMijMd_wvgYHc5q_FYzOCcrCzRqEZQdiZK5dD2MoMj7uQQnKaknoxR7d_njc44bzbWrSFeuuVPtsl723mS9dVtl5Kov3-Xmz3rZwLi67XZYcQ_y297eH_w5msjBZi-ZE7v_Hk9A2GEQdQVWB5zR9NPES4Ubq_HeqjbBrTOR3Gk1J0136DqfBugSJjzybdEd68TCtpMZvx0BeOiXcKIhKsOfr1cnGmrXS9NkOhHWKF7YBE_1x5NI_cgpLO2Gfn20Hds_unrERCxS-iTdBTJfBRP0wDFjkUzBYInsVoAN92m3Fdc97dNdetn2KR8uk79j9KEVfWhDH4r0oRV96L2hDX2opQ9t6ENb-tCaPj_I1fFR9_DEqyZteIoHovDQQ_EVcJXFeKZAMxniZw2Zjmy4LH1gJjAIXGJHOBquFecRoLMpYhtQiIytkJnB_QBWCcXbAsBYSKUAnEGccki0tMmy0BifmTXy072ymwfXTuWmfpnrn65skLmWeJtk1uD3F7bQGSzkdgnfKwYTX74
link.rule.ids 786
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Formulation+factors+affecting+the+release+of+ezetimibe+from+different+liquisolid+compacts&rft.jtitle=Pharmaceutical+development+and+technology&rft.au=Khanfar%2C+M&rft.au=Sheikh+Salem%2C+M&rft.au=Hawari%2C+R&rft.date=2013-03-01&rft.eissn=1097-9867&rft.volume=18&rft.issue=2&rft.spage=417&rft_id=info:doi/10.3109%2F10837450.2012.680594&rft_id=info%3Apmid%2F22530561&rft_id=info%3Apmid%2F22530561&rft.externalDocID=22530561